Insider Selling: Celcuity (NASDAQ:CELC) Director Sells 25,000 Shares of Stock

Key Points

• Director sale: Celcuity director David Dalvey sold 25,000 shares on May 4 at an average $140.68 for ~$3.517M under a pre‑arranged Rule 10b5‑1 plan, leaving him with 65,000 shares (a 27.78% cut to his stake).
• Major clinical catalyst: Celcuity’s gedatolisib beat Novartis’ Piqray in a Phase‑III study with a reported survival benefit in PIK3CA+ metastatic breast cancer, sparking buying interest, takeover speculation and price‑target increases from firms like Guggenheim and Needham.
• Valuation and near‑term risk: The stock is trading near its one‑year high (~$139.44) after a rapid rally and a ~13x year surge, prompting debate over upside potential, modest analyst downgrades/estimate trims and increased odds of short‑term profit‑taking.

Celcuity, Inc. (NASDAQ:CELC - Get Free Report) Director David Dalvey sold 25,000 shares of the firm's stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the transaction, the director owned 65,000 shares in the company, valued at $9,144,200. This represents a 27.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Get Celcuity SMS alerts:

Sign Up

Celcuity Price Performance

Shares of NASDAQ CELC traded down $2.25 during mid-day trading on Wednesday, reaching $139.44. 801,530 shares of the company traded hands, compared to its average volume of 798,960. Celcuity, Inc. has a fifty-two week low of $9.51 and a fifty-two week high of $151.02. The company has a debt-to-equity ratio of 3.20, a current ratio of 10.55 and a quick ratio of 10.55. The firm has a market cap of $6.74 billion, a PE ratio of -36.79 and a beta of 0.09. The stock has a fifty day simple moving average of $115.27 and a 200-day simple moving average of $103.28.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.97) EPS for the quarter, beating analysts' consensus estimates of ($1.06) by $0.09. Equities research analysts anticipate that Celcuity, Inc. will post -3.97 EPS for the current fiscal year.

Key Headlines Impacting Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Phase‑III headline: gedatolisib outperformed Novartis’ Piqray and showed a survival benefit in PIK3CA+ metastatic breast cancer — the clinical win is the primary fundamental catalyst that drove recent buying and acquisition speculation. Celcuity’s gedatolisib beats Novartis’ Piqray in phase 3
• Positive Sentiment: Analyst support: Guggenheim reiterated a Buy and other firms (Needham) issued positive forecasts and price‑target increases, reinforcing investor confidence and fueling takeover chatter. Guggenheim Keeps Their Buy Rating on Celcuity (CELC) Needham & Company LLC Issues Positive Forecast for Celcuity
• Neutral Sentiment: Valuation debate: commentary asks whether a ~13x one‑year surge leaves meaningful upside from here — this frames mixed investor sentiment despite the clinical win. Is It Too Late To Consider Celcuity (CELC) After A 13x One Year Surge?
• Negative Sentiment: Near‑term estimate trims: HC Wainwright slightly lowered Q1–Q3/Q2 2026 EPS forecasts (small downgrades) — a signal that near‑term cash burn, timing of revenues or costs could be risk factors even as they lift long‑term projections. (Research note released 5/4/2026)
• Negative Sentiment: Technical/profit‑taking pressure: stock is trading near its 1‑year high after a rapid rally; modestly elevated volume and the high headline valuation increase the odds of short‑term pullbacks as some investors lock in gains.

Wall Street Analysts Forecast Growth

CELC has been the topic of a number of research analyst reports. Needham & Company LLC raised their price objective on shares of Celcuity from $122.00 to $157.00 and gave the company a "buy" rating in a research note on Monday. Guggenheim raised their price objective on shares of Celcuity from $135.00 to $165.00 and gave the company a "buy" rating in a research note on Monday. Citigroup reiterated an "outperform" rating on shares of Celcuity in a research note on Monday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Celcuity in a research note on Monday, April 20th. Finally, Wolfe Research restated an "outperform" rating and issued a $110.00 price target on shares of Celcuity in a research report on Thursday, March 12th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Celcuity has a consensus rating of "Moderate Buy" and an average price target of $134.50.

Hedge Funds Weigh In On Celcuity

A number of hedge funds have recently modified their holdings of the stock. NEA Management Company LLC grew its holdings in shares of Celcuity by 64.9% in the 4th quarter. NEA Management Company LLC now owns 3,535,561 shares of the company's stock worth $352,637,000 after acquiring an additional 1,391,300 shares during the last quarter. Avoro Capital Advisors LLC acquired a new position in shares of Celcuity in the 4th quarter worth $310,302,000. Soleus Capital Management L.P. grew its holdings in shares of Celcuity by 17.0% in the 2nd quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company's stock worth $40,208,000 after acquiring an additional 437,696 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Celcuity by 10.7% in the 4th quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company's stock worth $227,351,000 after acquiring an additional 220,386 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of Celcuity by 126.6% in the 4th quarter. State Street Corp now owns 1,637,687 shares of the company's stock worth $163,343,000 after acquiring an additional 914,887 shares during the last quarter. 63.33% of the stock is currently owned by institutional investors and hedge funds.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.